# Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

> **NCT07573215** · — · AVAILABLE · sponsor: **Revolution Medicines, Inc.**

## Conditions studied

- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreas Adenocarcinoma
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenocarcinoma
- Pancreatic Adenosquamous Carcinoma

## Interventions

- **DRUG:** daraxonrasib

## Key facts

- **NCT ID:** NCT07573215
- **Lead sponsor:** Revolution Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07573215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07573215, "Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT07573215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*